Q2 ven­ture in­vest­ing slows a tad, but the big mon­ey still flows in­to biotech

Ven­ture in­vest­ing in biotech dur­ing the sec­ond quar­ter slowed some­what from the blis­ter­ing pace set in 2015, but the field still racked up an­oth­er $1.7 bil­lion, eas­i­ly sur­pass­ing the mark for pre­vi­ous years and leav­ing 2016 on track to rich­ly sup­port the big new wave of drug de­vel­op­ers in or near the clin­ic.

That’s the bot­tom line in the tal­ly of ven­ture rounds from the Mon­eyTree Re­port by Price­wa­ter­house­C­oop­ers and the Na­tion­al Ven­ture Cap­i­tal As­so­ci­a­tion, based on da­ta from Thom­son Reuters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER